Abstract
From July 1990 to March 1996, 112 children with stage III or IV B-cell non-Hodgkin's lymphoma (B-NHL) with up to 70% FAB L3-type blasts (n= 42) in the bone marrow without central nervous system (CNS) disease were treated on the United Kingdom Children Cancer Study Group (UKCCSG) 9002 protocol (identical to the French LMB 84). The median age was 8.3 years. There were 81 boys and 31 girls. According to the extent of the primary disease, patients were sub-staged into three groups: IIIA with unresectable abdominal tumour (n= 39); IIIB with abdominal multiorgan involvement (n= 57) and IIIX with extra-abdominal primary lymphoma often presenting as pleural effusion (n= 16). Univariate and multivariate analyses were carried out to evaluate the prognostic significance of lactate dehydrogenase (LDH) level at diagnosis, the sub-stage and the time to achieve complete remission (CR). With a median follow up of 48 months (range 12–92), the overall and event free survival (EFS) is 87% (95% confidence interval (CI) 79.2–92.1%) and 83.7% (95% CI 76.3–89.2%) respectively. Six patients (5.4%) never achieved CR, of whom one is alive following high-dose therapy. Eight patients (7.1%) relapsed after achieving CR, three are alive after second-line therapy. There were three early toxic deaths (2.7%), mainly from infection, and one late death from a second cancer. There was no significant difference in EFS according to LDH level at diagnosis, the sub-stage or the time to CR. This study confirms the overall good prognosis and low rate of toxic deaths in patients with advanced B-NHL treated with this intensive regimen. No significant difference in EFS according to the sub-stage, the time to achieve CR or LDH level at diagnosis making it difficult to identify a group that should not receive intensive therapy. © 2000 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Al-Attar A, Pritchard J, Al-Saleem T, Al-Naimi M, Alash N and Atra A (1986) Intensive chemotherapy for non-localised Burkitt's lymphoma. Arch Dis Child 61: 1013–1019
Al-Attar A, Atra A, Al-Bagdadi R, Al-Naimi M, Al-Saleem T and Pritchard J (1989) ‘Debulking’ surgery is unnecessary in advanced abdominal Burkitt lymphoma in Iraq. Br J Cancer 59: 610–612
Allegretta GJ, Weismann SJ and Altman AJ (1985) Metabolic and space-occupying consequences of cancer and cancer treatment. Ped Clin N Am 32: 601
Atra A, Gerrard M, Hobson R, Imeson JD, Ashley S and Pinkerton CR on behalf of the UKCCSG (1998) Improved cure rate in children with B-cell acute lymphoblastic leukaemia (B-ALL) and Stage IV B-cell non-Hodgkin's lymphoma (B-NHL) – results of the UKCCSG 9003 protocol. Br J Cancer 77: 2281–2285
Bowman WP, Shuster JJ, Cook B, Griffin T, Behm F, Pullen J, Link M, Head D, Carroll A, Berard C and Murphy S (1996) Improved survival for children with B-cell acute lymphoblastic leukaemia and stage IV small noncleaved-cell lymphoma: a pediatric oncology study group. J Clin Oncol 14: 1252–1261
Cairo M, Krailo M, Morse M, Hutchinson R, Harris R, Kjeldsberg C, Kadin M, Radel E, Steinherz L and Meadow A (1996) Disseminated non-lymphoblastic non-Hodgkin's lymphoma (DNLHL) of childhood: a randomised phase II trial of short intensive treatment (abstract 093). Ann Oncol 7: 20
Chilcote RR, Krailo M, Kjeldsberg C, Kadin M, Steinherz P, Coccia P, Morse M, Reaman G and Hammond G (1991) Daunomycin plus COMP therapy in childhood non-lymphoblastic lymphomas. Proc Am Soc Clin Oncol 10: 289
Hann IM, Eden OB, Barnes J and Pinkerton CR (1990) MACHO chemotherapy for Stage IV B-cell lymphoma and B-cell acute lymphoblastic leukaemia of childhood. Br J Haem 76: 359–364
Kaplan EL and Meier P (1958) Non-parametric estimation from incomplete observations. J Am Stat Ass 53: 457–481
Lynch RE, Kjellstrand CM and Coccia PF (1977) Renal and metabolic complications of childhood non-Hodgkin's lymphoma. Semin Oncol 4: 235
Miron I, Frappaz D, Brunat-Mentingy M, Combaret V, Buclon M, Bouffet E, Thiesse P, Ragg S, Bailly C and Philip T (1997) Initial management of advanced Burkitt lymphoma in children: Is there still a place for surgery?. Ped Hem Oncol 14: 555–561
Patte C, Philip T, Rodary C, Bernrd A, Zuker JM, Bernard JL, Robert A, Railland X, Benz-Lemoine E and Demeocq F (1986) Improved survival rate in children with Stage III and IV B-cell non-Hodgkin's lymphoma and leukaemia using multi-agent chemotherapy: results of a study of 114 children from the French Pediatric Oncology Society. J Clin Oncol 4: 1219–1226
Patte C, Leverger G, Perel Y, Rubie H, Otten J, Nelken B, Gentet JC, De Lumley L, Berendt H and Brugleres L, for the SFOP (1990) Updated results of the LMB 86 protocol of the French Pediatric Oncology Society (SFOP) for B-cell non-Hodgkin's lymphomas 9B-NHL with CNS involvement (CNS+) and B-ALL (abstract 22). Med Ped Oncol 18: 397
Patte C, Philip T, Rodary C, Zuker JM, Behrendt H, Gentet JC, Lamagnere JB, Otten J, Dufillot D, Pein F, Caillou B and Lemerle J (1991) High survival rate in advanced stage B cell lymphoma and leukaemias without CNS involvement with a short intensive polychemotherapy: results from the French Pediatric Oncology Society of a randomised trial of 216 children. J Clin Oncol 9: 123–132
Patte C, Michon J, Berendt H, Leverger G, Frappaz D, Robert A, Mechinaud F, Bertrand Y, Perel Y, Coze C and Nelken B on behalf of the SFOP (1997) Updated results of the LMB 89 protocol of the SFOP (French Pediatric Oncology Society) for childhood B-cell lymphoma and leukaemia (ALL). Med Ped Oncol 29: 358
Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J and Smith PG (1977) Design and analysis of randomised clinical trials requiring prolonged observation of each patient. II Analysis and examples. Br J Cancer 35: 1–39
Philip T, Lenoir GM, Bryon PA, Souillet G, Philippe N, Freycon F and Brunat-Mentigny M (1982) Burkitt type lymphoma in France among non-Hodgkin malignant lymphomas in Caucasian children. Br J Cancer 45: 670–678
Philip T, Pinkerton CR, Biron P, Ladjadj Y, Bouffet E, Souillet G, Philippe N, Frappaz D, Freycon F, Chauvin F and Brunat-Mentignj M (1987) Effective multi-agent chemotherapy in children with advanced B-cell lymphoma: who remains the high risk patient?. Br J Haematol 65: 159–164
Philip T, Hartmann O, Pinkerton R, Zuker JM, Gentet JC, Lamagnere JP, Berhendt H, Perel Y, Otten J, Lutz P, Rodary C, Caillou B, Bayle C, Chauvin F and Patte C (1993) Curability of relapsed childhood B-cell non-Hodgkin's lymphoma after intensive first line therapy: A report from the Societe Francaise d'Oncologie Pediatrique. Blood 81: 2003–2006
Pinkerton CR, Hann I, Eden OB, Gerrard M, Berry J and Mott MG on behalf of the United Kingdom Children's Cancer Study Group (1991) Outcome in Stage III non-Hodgkin's lymphoma in children (UKCCSG study NHL 86) – How much treatment is needed?. Br J Cancer 64: 583–587
Reiter A, Schrappe M, Parwaresch R, Henze G, Muller-Weihrich S, Sauter S, Sykora KW, Ludwig WD, Gander H and Riehm H (1995) Non-Hodgkin's lymphomas of childhood and adolescence: results of a treatment stratified from biological subtypes and stage – a report of the Berlin-Frankfurt-Munster Group. J Clin Oncol 13: 359–372
Reiter A, Schrappe M, Tiemann M, Yakisan E, Zimmermann M, Ebell W, Meyer U, Schirg E, Sykora KW, Pluss HJ, Mann G, Henze G, St. Muller-Weihrich,, Gadner H, Parwaresch R and Riehm H, for the BFM group, Medizinische Hochschule, Hannover, Germany (1997) Treatment results for the B-cell lymphomas and acute B-cell leukaemia in the German-Austrian-Swiss study NHL-BFM 90. A report of the BFM group. Risk group definition, treatment strategy and preliminary results for B-cell neoplasias in trial NHL-BFM 90. Med Ped Oncol 29: 358 (abstr)
Rothman KJ (1978) Estimation of confidence limits for the cumulative probability of survival in life table analysis. J Chronic Dis 31: 557–560
Sandlund J, Crist W, Fairclough D, Berard C and Pui CH (1990) Pleural effusion confers a worse treatment outcome for children with stage III abdominal small noncleaved cell non-Hodgkin's lymphoma. Proc ASCO 9: 1065
SAS (1991) The PHREG procedure SAS Institute Inc: Cary, NC
Sweetenham JW, Liberti G, Pearce R, Taghipour G, Santini G and Goldstone AH (1994) High-dose therapy and autologous bone marrow transplantation for adult patients with lymphoblastic lymphoma: results of the European group for bone marrow transplantation. J Clin Oncol 12: 1358–1365
Author information
Authors and Affiliations
Consortia
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Atra, A., Imeson, J., Hobson, R. et al. Improved outcome in children with advanced stage B-cell non-Hodgkin's lymphoma (B-NHL): results of the United Kingdom Children Cancer Study Group (UKCCSG) 9002 protocol. Br J Cancer 82, 1396–1402 (2000). https://doi.org/10.1054/bjoc.1999.1083
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.1999.1083